Recursion is using AI and machine learning to accelerate drug research and development. The stock has been under pressure amid an uncertain near-term financial outlook. Several clinical updates from ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...